Treatment of malignant hypercalcaemia

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 521-527

  Hurtado, J ^a   Esbrit, P ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Bisphosphonates; Cancer; Hypercalcaemia; Malignancy; Osteolysis

Indexed keywords

ALENDRONIC ACID; AMIFOSTINE; AMINOTRANSFERASE; ANTINEOPLASTIC ANTIBIOTIC; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM ION; CLODRONIC ACID; CREATININE; ETIDRONIC ACID; GALLIUM NITRATE; HYDROXYAPATITE; IBANDRONIC ACID; INTERLEUKIN 1; MITHRAMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PYROPHOSPHORIC ACID DERIVATIVE; RAS PROTEIN; RISEDRONIC ACID; TILUDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZOLEDRONIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FEVER; HUMAN; HYPERCALCEMIA; KIDNEY TUBULE ABSORPTION; MYELOMA; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOLYSIS; PARANEOPLASTIC SYNDROME; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REHYDRATION; REVIEW; SYMPTOMATOLOGY; TACHYPHYLAXIS; THROMBOCYTOPENIA;

DIPHOSPHONATES; FLUID THERAPY; HUMANS; HYPERCALCEMIA;

EID: 0036097125     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.521     Document Type: Review

References (68)

1. Hypercalcemia of malignancy
2. Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations
3. Hypercalcaemia. What does it signify?
4. Quantitative bone histology in the hypercalcaemia of malignant disease
5. Molecular mechanisms of osteolytic bone metastases
6. Mechanisms of the development of osteoblastic metastases
7. Osteolysis and cancer
8. Parathyroid hormone-related protein and hypercalcaemia
9. Parathyroid hormone-related protein: Structure, function and measurement
10. Comparison of two immunoradiometric assays for parathyroid hormone-related protein in the evaluation of cancer patients with and without hypercalcaemia
11. Parathyroid hormone-related protein, parathyroid hormone and vitamin D in hypercalcaemia of malignancy
12. Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate
13. Copurification of calcium transport-stimulating and DNA synthesis-stimulating agents with parathormone-like activity isolated from the hypercalcaemic strain of the Walker 256 tumour
14. Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256
15. Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: Implications for the pathogenesis of humoral hypercalcaemia of malignancy
16. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity
17. Parathyroid hormone-related peptide can function as an autocrine growth factor in human renal cell carcinoma
18. Proliferative effect of parathyroid hormone-related protein on the hypercalcemic Walker 256 carcinoma cell line
19. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma
20. Hypercalcemia of malignancy-New insights into an old sydrome
21. Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients
22. Evaluation and treatment of hypercalcemia
23. Extracellular calcium-sensing receptor: Implications for calcium and magnesium handling in the kidney
24. Calcium transport in renal epithelial cells
25. Acute treatment of hypercalcemia with furosemide
26. Bone metastases and tumour-induced hypercalcemia
27. 3rd Mithramycin treatment of hypercalcemia
28. The hypercalcemia of malignancy: Pathogenesis and management
29. Bisphosphonates: From the laboratory to the clinic and back again
30. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line
31. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
32. Decreased efficacy of bisphosphonates for recurrences of tumour-induced hypercalcemia
33. Therapy of hypercalcemia of malignancy
34. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases. A prospective randomised placebo-controlled multi-centre study
35. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate
36. Current use of bisphosphonates in oncology
37. Clodronate
38. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
39. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type
40. High dose pamidronate: Clinical and biochemical effects in metastatic bone disease
41. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia
42. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein
43. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
44. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
45. Comparative tolerability of drug therapies for hypercalcemia of malignancy
46. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
47. A dose-finding study of zoledronate in hypercalcemic cancer patients
48. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
49. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy
50. Calcitonin
51. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia
52. Gallium nitrate for the treatment of bone metastases
53. Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells
54. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma
55. Response to treatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone
56. Use of bisphosphonates in cancer patients
57. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
58. A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain
59. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
60. Low-dose gallium nitrate for prevention of osteolysis in myeloma: Results of a pilot randomized study
61. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP and 1,25-(OH) 2 D 3
62. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumours associated with humoral hypercalcemia of malignancy
63. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
64. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumour-bearing rats treated with WR-2721
65. In vivo nuclear uptake of a vitamin D analog (OCT) in different tumour cell populations of FA-6 cancer xenograft in nude mice by receptor autoradiography
66. The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line
67. The physiology of parathyroid hormone-related protein
68. Molecular mechanism of action of parathyroid hormone-related peptide in hypercalcemia of malignancy: Therapeutic strategies